Vendor Intelligence Report: Bopeptide Biotechnology

Published 3 Jul 2026. 21-page investigative report on who is behind Bopeptide Biotechnology: corporate records, ownership, affiliate networks, and the vendor's lab-testing record. The first 3 pages are free to read on this page.

Researched and published by Finnrick Analytics. Reports draw on corporate records, affiliate-network analysis, and Finnrick's own laboratory testing record; vendors can challenge findings through the formal objections process at finnrick.com/vendor-support/objections.

Executive summary

Across 8 Finnrick lab tests for Bopeptide Biotechnology, the overall pass rate is 75%: 6 pass and 2 fail. The record is narrow but useful: it covers only Retatrutide and Tirzepatide, and the two products move almost in parallel. Neither stands out as a safer in-catalogue pivot; both support cautious, lot-verified buying rather than blind reorder confidence.

The non-lab record is young and split. Finnrick’s supplied vendor URL, botaimaoyi.com/en, was inaccessible during the field run, and the latest reviewed archive showed an under-construction notice. bopeptide.com was active as the de facto public site, but its short registration history and renewal window make exact-channel verification part of the buying process, not an afterthought.

Corporate signals are similarly incomplete. The active site presents Nanjing Bopeptide Trading Co., Ltd.; a GuideChem listing separately identifies Hefei Bopeptide Biotechnology Co., Ltd. with Kingsley Liu as project manager. The report ties those records by branding and commercial context, while withholding a clean ownership claim because Chinese primary-registry access was not obtained.

Bopeptide gets one favorable narrow mark: the covered X/web sweep did not document promoters, coupon codes, referral links, or an obvious affiliate-hype network. That is not the same as a mature reputation record. No public batch-COA library, authorized-channel list, or open verification portal was found, so buyers should treat untested catalogue items, including Semaglutide and older archived listings, as outside Finnrick’s evidence base.

Inside the full report:

  • Product-level Finnrick pass/fail analysis and methodology-divergence charts for Retatrutide and Tirzepatide
  • WHOIS and Wayback timeline comparing botaimaoyi.com with the active Bopeptide domain
  • Entity mapping for Nanjing Bopeptide Trading Co., Ltd. and Hefei Bopeptide Biotechnology Co., Ltd.
  • GuideChem and contact-channel evidence, including the Kingsley Liu listing and Nanjing/Hong Kong contact split
  • COA, authorized-channel, Reddit, affiliate-scan, and import/export dead-end analysis

Risk assessment

  • Official-channel continuity and authenticity-verification risk — high: The supplied botaimaoyi.com/en site is inaccessible and has shown under-construction status in archive; bopeptide.com is active but expires September 29, 2026, and no public authorized-channel or COA-verification system was found.
  • Retatrutide and Tirzepatide batch-quality risk — medium: Finnrick records show 8 tests, with 6 pass and 2 fail; Retatrutide and Tirzepatide each show 4 tests with 3 pass and 1 fail, requiring lot-specific verification.
  • Corporate-accountability and registry-verification risk — medium: Records connect Nanjing Bopeptide Trading Co., Ltd. and Hefei Bopeptide Biotechnology Co., Ltd. by brand and contacts, but ownership, legal relationship, and registry details were not verified from Chinese primary records.